Whole-Genome Analysis of 7,851 Families Identifies Impact of Assisted Reproductive Technology and Paternal De Novo Mutations on Neonatal Outcomes
Background
The use of Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF) procedures to overcome infertility, is on the rise worldwide. As the population of older pregnancies grows, the proportion of newborns born with the help of reproductive medicine is steadily rising. In clinical settings, it has been consistently reported that children born through these procedures show subtle differences in pregnancy outcomes, such as low birth weight or preterm birth, compared to naturally conceived infants.
Previously, the academic community interpreted these differences primarily as a result of biological parental aging. It was well known that genetic mutations accumulate in germ cells as both males and females age. However, it remains unclear whether ART procedures themselves, such as in vitro fertilization or intracytoplasmic sperm injection (ICSI), independently affect embryonic genetic variations, or whether these variations are directly linked to adverse birth outcomes. This was due to a lack of large-scale family-based data with high-depth, precise whole-genome tracking.
Key Findings
Researchers performed high-resolution Whole-Genome Sequencing (WGS) analysis on a cohort of 7,851 parent-offspring family pairs. Based on this, they precisely classified the origins of De Novo Mutations (DNM) in the offspring generation into maternal, paternal, and post-zygotic mutation stages.
The analysis revealed that the patterns of specific types of parent-derived and post-zygotic mutations vary depending on the specific ART procedures used. This association remained independent even after statistically adjusting for parental age at conception. This suggests that exposure to in vitro environments or manipulation during specific procedural steps may contribute to mutation formation during early embryonic development.
Furthermore, statistical mediation analysis revealed that the increased paternal mutational burden significantly mediates the effects of advanced parental age and ART on gestational duration and key birth indicators. The study provided data-driven proof that the accumulation of mutations transmitted from the paternal side acts as a functional mediator, going beyond a simple biological marker to exert a substantial impact on maintaining gestational length and early vital indicators in newborns.
Significance and Outlook
This study represents a significant academic advance by mapping the pathways through which assisted reproductive technology (ART) and parental aging influence next-generation genomes and birth outcomes at the molecular level. It opens the possibility for the quantitative assessment of paternal genetic variation to develop into a new clinical indicator for predicting pregnancy duration and neonatal health status.
A challenge to consider in the generalization process is that the study was centered on a specific population cohort. Further validation reflecting diverse ethnic backgrounds and regional differences in clinical protocols is necessary. Follow-up research is also required to verify in detail the biological mechanisms by which specific procedural variables—such as embryo culture medium composition, freezing and thawing techniques, and sperm selection technology—affect mutation occurrence, using in vitro experiments and animal models.
Nature Medicine, Published online: 14 September 2026; doi:10.1038/s41591-026-04676-0Whole-genome sequencing of 7,851 parent–offspring families enabled the identification of parent-of-origin and post-zygotic de novo mutations that were associated with distinct procedures of assisted reproductive technology (ART), independently of parental age at conception. Increased paternal mutational burden statistically mediates the effects of advanced parental age and ART on gestational duration and other birth outcomes.
In infertility clinics and reproductive medicine clinical settings, these results provide practical standards for establishing patient-customized protocols. While previous evaluations focused on maternal age and uterine condition, the introduction of precision diagnostic panels to pre-screen sperm genomic integrity and paternal mutational burden is expected to accelerate.
This is predicted to drive demands for process improvements across the reproductive medicine medical device and culture media manufacturing industries, including the development of optimized equipment to minimize embryo culture conditions and in vitro exposure time, as well as the standardization of intracytoplasmic micro-manipulation techniques. It can also be directly utilized to establish customized medical strategies that identify high-risk groups, such as older couples or patients undergoing complex procedures, for early screening and linkage to intensive perinatal management.